Pfizer wins EU approval for $15 billion Hospira buy

BRUSSELS (Reuters) - U.S. drugmaker Pfizer gained European Union antitrust approval on Tuesday for its proposed $15 billion acquisition of U.S. rival Hospira after pledging to sell some drugs to allay competition concerns.